Immunoglobulin A nephropathy (IgAN)
IgA nephropathy: A real-world comparison between disease severity, symptom burden, and treatment satisfaction reported by patients and nephrologists
Nicholas R Medjeral-Thomas, Carolina Aldworth, Julia Kattlun, Aneesh Thomas George, Jonathan de Courcy, Emma Chatterton
Symptom control with currently available immunoglobulin A nephropathy treatment: Results from a real-world survey in eight countries
Wei Chen, Serge Smeets, Luis Prieto, Michel Kroes, Aneesh Thomas George, Jonathan de Courcy, Jade Garratt-Wheeldon
Immunoglobulin A nephropathy: Patient-reported symptoms prior to first consultation and diagnosis - results from a real-world survey
Richard Lafayette, Michel Kroes, Julia Kattlun, Carolina Aldworth, Aneesh Thomas George, Jonathan de Courcy, Emma Chatterton
The diagnostic journey of patients with immunoglobulin A nephropathy: Data analysis of a real-world survey
Michel Kroes, Serge Smeets, Aneesh Thomas George, Luis Prieto, Jonathan de Courcy, Jade Garratt-Wheeldon
Complement3 glomerulopathy (C3G)
Real-world signs and symptoms at diagnosis in patients with C3 glomerulopathy - interim results from a multi-country study
Clare Proudfoot, Katharina Pannagl, Jennifer Nguyen, Andrea King, Kathleen Murphy, Jonathan de Courcy, Richard Lafayette
C3 glomerulopathy current therapy and real-world management - interim results from a multi-country study
Clare Proudfoot, Katharina Pannagl, Briana Ndife, Andrea King, Kathleen Murphy, Susanna Libby, Richard Lafayette
Pharmacokinetics and pharmacodynamics of iptacopan
Japanese and Whites share similar iptacopan pharmacokinetics and pharmacodynamics
Robert Schmouder, Guido Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki
Effect of renal impairment on iptacopan pharmacokinetics
Robert Schmouder, Giulia Lestini, Christian Bartels, Irina Baltcheva, Guido Junge, Kenneth Kulmatycki
Human pharmacokinetics of multiple, steady-state dosing of iptacopan
Robert Schmouder, Guido Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki